MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that may arise when high magnetic fields interact with radiation beams. However, the company faces critical operational challenges following recent bankruptcy proceedings, impacting its competitive positioning and market availability.
Cyborg Score Rationale
ViewRay filed a voluntary petition for reorganization under Chapter 11 on July 16, 2023, which was converted to Chapter 7 on October 26, 2023. The company appears delisted as of September 2023, limiting current operational and financial transparency and raising questions about ongoing business viability.
Top Insights
Proprietary MRI-guided radiation therapy addresses critical unmet needs in precision oncology with real-time tissue tracking
Company filed Chapter 11 bankruptcy (July 2023) converted to Chapter 7 liquidation (October 2023), indicating severe financial distress
Last recorded trade September 27, 2023; appears delisted from public markets with stock trading on OTC markets at nominal prices
Trailing twelve-month revenue approximately $100M before bankruptcy, indicating niche market with limited commercial scale
Named Competitors
Accuray — Radiation therapy systems for cancer treatment
CyberKnife — Robotic radiosurgery system
Recent Developments
(July 2023) Filed voluntary petition for Chapter 11 reorganization under U.S. Bankruptcy Court
(October 2023) Chapter 11 petition converted to Chapter 7 liquidation
(September 2023) Last recorded stock trade occurred; company delisted from exchange
Open the full interactive ViewRay, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.